Behavioral Health Business August 12, 2024
Laura Lovett

After years of clinical trials and industry anticipation, the FDA has red-lighted Lykos Therapeutics’ midomafetamine (MDMA)-assisted therapy for treating PTSD.

The agency requested that Lykos conduct an additional Phase 3 trial to further study the therapy’s safety and efficacy. This comes after FDA advisors voted down MDMA therapy in June, saying the treatment lacked data about the risks of the therapy and the efficacy.

“The FDA request for another study is deeply disappointing, not just for all those who dedicated their lives to this pioneering effort, but principally for the millions of Americans with PTSD, along with their loved ones, who have not seen any new treatment options in over two decades,” Amy Emerson, CEO of Lykos Therapeutics, said in...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency

Share This Article